VIFOR-PHARMA
5.5.2020 13:03:14 CEST | Business Wire | Press release
Regulatory News:
Vifor Pharma announced that its partner, Akebia Therapeutics, Inc ., today reported positive top-line results from INNO2 VATE, Akebia’s global phase-III cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anaemia due to Chronic Kidney Disease (CKD) in adult dialysis-dependent patients (DD-CKD). Upon successful completion of its phase-III program, which includes Akebia’s studies of vadadustat for the treatment of anemia due to CKD in non-dialysis patients, Akebia plans to submit a New Drug Application (NDA) for vadadustat for the treatment of anemia due to CKD in dialysis dependent and non-dialysis dependent patients, to the U.S. Food and Drug Administration (FDA).
“We are delighted with the positive top-line data from Akebia’s INNO2 VATE global phase-III global study of vadadustat for the treatment of anemia due to CKD in dialysis patients,” comments Stefan Schulze, Vifor Pharma President of the Executive Committee and Chief Operating Officer, “By successfully meeting its primary efficacy and cardiovascular endpoints, we believe the INNO2 VATE data positions vadadustat as a potential new oral standard of care for treating all populations of dialysis patients, including both incident and prevalent dialysis patients with anemia due to CKD, subject to its approval. We look forward to working with Akebia to bring vadadustat, upon approval, to our dialysis patients.”
Vifor Pharma was granted an exclusive license to sell vadadustat to Fresenius Kidney Care dialysis centers and to specific third party dialysis organisations that together account for approximately 60% of the dialysis patients in the US, subject to approval of vadadustat by the FDA and its inclusion in Medicare’s bundled reimbursement model for dialysis, or reimbursement using the Transitional Drug Add-On Payment Adjustment (TDAPA), and a milestone payment by Vifor Pharma.
About Akebia’s Global phase-III INNO2 VATE Program
Akebia’s public announcement highlighted that its global INNO2 VATE program is a cardiovascular outcomes program which includes two separate phase-III studies (Correction/Conversion and Conversion ) and which collectively enrolled 3,923 dialysis-dependent patients with anemia due to chronic kidney disease (CKD). Both INNO2 VATE studies are global, multicenter, open label (sponsor blinded), active-control (darbepoetin alfa- an injectable erythropoiesis stimulating agent (ESA)), non-inferiority studies. According to Akebia’s announcement: “Vadadustat achieved the primary and key secondary efficacy endpoint in each of the two INNO2 VATE studies, demonstrating non-inferiority to darbepoetin alfa as measured by a mean change in hemoglobin (Hb) between baseline and the primary evaluation period (weeks 24 to 36) and secondary evaluation period (weeks 40 to 52). Vadadustat also achieved the primary safety endpoint of the INNO2 VATE program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE), which is a composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke across both INNO2 VATE studies. Each analysis was measured against non-inferiority (NI) margins agreed upon with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).”
About Vadadustat
Vadadustat is Akebia’s oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD. Vadadustat is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational therapy and is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Please visit https://akebia.com/pr-552020/ to access the complete public announcement from Akebia Therapeutics, which does not form a part of this release.
Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incode Acquires Identiq to Expand Its Privacy-First Architecture for Identity and Fraud Prevention25.6.2026 15:00:00 CEST | Press release
Extends its privacy-by-design architecture with Identiq’s patented cryptographic technology that enables organizations to share fraud signals without sharing sensitive data. Incode Technologies, a global leader in AI-powered identity verification and fraud prevention, today announced that it has completed the acquisition of Identiq, a company specializing in privacy-enhancing cryptographic solutions for peer-to-peer anti-fraud collaboration. Incode announced this acquisition as part of a $100 million commitment to advancing its original privacy-preserving identity infrastructure. The funds will be used to enhance on-device processing capabilities, continue R&D in privacy-enhancing technologies, and expand engineering resources and its global footprint. “We have always believed that privacy and fraud prevention are not a tradeoff, but part of the same problem, solved together or not at all,” said Ricardo Amper, Founder and CEO of Incode. “Identiq is the piece that enhances our Privacy b
Gurobi Introduces New Optimization Game Set in a Fast-Paced Coffee Shop25.6.2026 15:00:00 CEST | Press release
Gurobean, companion to the “Burrito Optimization Game” with 85,000+ plays, introduces advanced concepts like nonlinearity and uncertainty. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of Gurobean: The Coffee Optimization Game, a new educational game that brings nonlinearity, simulation, and decision-making under uncertainty to life. Following the success of the Burrito Optimization Game—which has been played over 85,000 times by learners across the world since its launch in 2022—Gurobean places players behind the counter of a virtual coffee shop, where they must make critical decisions around pricing, staffing, queue management, inventory levels, and more. The free, interactive game furthers Gurobi’s ongoing commitment to open education, teaching players: The value of mathematical optimization How quickly real-world decision problems become too complex to solve by trial and error How nonlinearity and uncertainty make outcomes hard
AllUnity and Zebec Deploy EURAU-Powered Employee Benefits and Enterprise Payment Solutions on Stellar25.6.2026 14:59:00 CEST | Press release
AllUnity and Zebec today announced the launch of an EURAU-based employee benefits and enterprise payments program on the Stellar network. The pilot program aims to expand payroll and workforce payments in AllUnity's regulated euro stablecoin across its ecosystem, including its major enterprise clients and partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625883682/en/ Built on Stellar and powered by EURAU, AllUnity's regulated euro stablecoin, the program combines regulated digital currency with enterprise grade payroll and payments infrastructure purpose built for global value transfer. Employees participating in the pilot can receive benefits directly to digital wallets while accessing a growing range of spending, savings, and payment options through the Zebec platform. "Regulated stablecoins are increasingly moving from financial infrastructure to real world business applications," said Simon Babakhani, CEO of Z
2026 Esri User Conference to Focus on Creating a More Intelligent World with GIS25.6.2026 14:00:00 CEST | Press release
More Than 18,000 Attendees Expected for World's Largest GIS Conference in San Diego The 2026 Esri User Conference will be held from July 13 to 17 in San Diego, California. This year's theme is "GIS—Creating a more intelligent world." Jack Dangermond, president and founder of Esri, and Kristine Tompkins, president and cofounder of Tompkins Conservation, will be the keynote speakers in the Plenary Session. Esri, the global leader in geographic information system (GIS) technology, today announced speakers and the conference theme for the 2026 Esri User Conference. The conference will be held from July 13 to 17 at the San Diego Convention Center in San Diego, California. This year's theme of "GIS—Creating a more intelligent world" will emphasize how GIS turns the science of "where" into shared understanding and coordinated action—at the scale of communities, enterprises, and the planet. Kristine Tompkins, president and cofounder of Tompkins Conservation, will join Esri president Jack Dange
Copeland Releases FY2025 Global Impact Report Highlighting Energy Efficiency, Safety and Innovation Progress25.6.2026 14:00:00 CEST | Press release
Scope 1 and Scope 2 greenhouse gas emissions declined nearly 20%1Near-term reduction targets validated by the Science Based Targets InitiativeGlobal Total Recordable Incident Rate improved to 0.21, outperforming the industry average by over 90% Copeland, a global leader in compression technologies and controls solutions, has released its second annual Global Impact Report. The report highlights the company’s Fiscal Year 2025 (FY25) progress across environmental sustainability, workplace safety and community impact, guided by its Purpose, Performance and People pillars. Copeland has advanced its sustainability commitments through three strategic areas of focus: Performance-Driven Decarbonization: Copeland reduced Scope 1 and Scope 2 greenhouse gas emissions by 20% year-over-year, advancing toward its Science Based Targets initiative (SBTi)-validated goal of a 55% absolute reduction by FY33, using FY23 as a baseline.2 Renewable energy procurement and onsite solar generation accounted for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom